Advances in Metastatic Breast Cancer: Antibody–Drug Conjugate Therapy for the Multidisciplinary Team

Register now for this live, 1-hour workshop to learn how medical oncologists, pharmacists, and nurses can effectively incorporate approved and emerging antibody–drug conjugates into the care of patients with metastatic breast cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Introduction: Background and Current Landscape of ADCs in Metastatic Breast Cancer
  • Application of Data and Therapeutic Options in Metastatic Breast Cancer
    • Selecting Second-line Therapy for HER2-Altered Metastatic Breast Cancer
    • HER2-Low Metastatic Breast Cancer
    • Selecting ADCs for TNBC
    • Adverse Event Identification and Management
  • Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer Session


Date / Time
Event Details


Sara Hurvitz, MD, FACP

Professor of Medicine
Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging data on antibody–drug conjugate therapies into clinical practice for patients with metastatic breast cancer.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with metastatic breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare the available antibody–drug conjugate therapies used in the treatment of metastatic breast cancer, considering antibody target, mechanism of action, overall construct, efficacy, and safety profile
  • Plan individualized treatment strategies for patients with HER2-low metastatic breast cancer, considering recent clinical data and expert recommendations
  • Select optimal second-line antibody–drug conjugate therapy for patients with HER2-positive metastatic breast cancer based on available clinical data and expert recommendations
  • Develop clinical strategies for the early identification and management of treatment-related symptoms associated with antibody–drug conjugates
  • Identify emerging targets for precision therapy with antibody–drug conjugates that may provide future treatment options for the treatment of metastatic breast cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-015-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.